Hypercapnic Respiratory Failure Clinical Trial
— KETOHSOfficial title:
Ketogenic Diet for Obesity Hypoventilation Syndrome
Verified date | June 2022 |
Source | Johns Hopkins University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Obesity hypoventilation syndrome (OHS) is a condition that occurs in small percentage of obese people that causes high carbon dioxide and low oxygen levels in the blood. OHS is associated with respiratory failure, pulmonary hypertension, and death. The cause of OHS is unclear. Since not all obese people develop OHS, it is believed that hormone imbalances can contribute to the breathing problem. Some diets can change the body's hormones. For example, low-carbohydrate, high fat "ketogenic" diets (KD) may decrease insulin and glucose levels and increase sensitivity to other hormones. The investigators hypothesize that a KD will improve breathing in OHS patients, even in the absence of weight loss.
Status | Completed |
Enrollment | 24 |
Est. completion date | June 28, 2022 |
Est. primary completion date | June 28, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Obesity (BMI=30 kg/m2) - Hypercapnia (PaCO2>45 or PvCO2>50) on blood gas, OR a sleep study with end-tidal/transcutaneous CO2 monitoring showing an awake CO2 level >50 - Participants without blood gas data may also have suspected OHS on the basis of serum bicarbonate >=28 mEq/L - Lack of an alternative pulmonary diagnosis that adequately explains hypercapnia. Note that a documented pulmonary diagnosis (e.g. chronic obstructive pulmonary disease (COPD) or asthma) per se will not necessarily exclude subjects, since OHS is often misdiagnosed as obstructive lung disease. Functional or radiographic data must corroborate the presence of the alternate diagnosis. - Subjects must have had a sleep study and clinical evaluation for sleep apnea. Most subjects with OHS are expected to have concomitant obstructive sleep apnea (OSA). This information is necessary to determine whether continuous positive airway pressure (CPAP)/noninvasive ventilation (NIV) will be used on the research sleep studies. Exclusion Criteria: - Concomitant participation in another weight loss or diet program - Patients with diabetes taking Sodium-glucose Cotransporter-2 (SGLT2) inhibitors (due to risk of diabetic ketoacidosis) - Patients with type 1 diabetes - Any patients with a history of diabetic ketoacidosis - Patients with incomplete sleep apnea diagnosis or management (i.e. those still acclimating to CPAP, or pending therapeutic decisions about OSA management) - Known or suspected abuse of narcotics or alcohol - Liver cirrhosis - Uncontrolled gout - History of chronic renal insufficiency requiring dialysis - Females who are pregnant, breast-feeding, or intending to become pregnant - Food allergies or diet restrictions that research nutritionists cannot accommodate FOLLOW THIS LINK TO SEE IF YOU QUALIFY: https://mrprcbcw.hosts.jhmi.edu/redcap/surveys/?s=RYX7DELK9Y |
Country | Name | City | State |
---|---|---|---|
United States | Johns Hopkins Bayview Medical Center | Baltimore | Maryland |
Lead Sponsor | Collaborator |
---|---|
Johns Hopkins University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Awake venous carbon dioxide (PvCO2) Level | Measured in mmHg. | Baseline (pre keto diet) and 2 weeks post keto diet | |
Secondary | Change in Venous pH | Measured in moles per liter. | Once per week, over 4 weeks | |
Secondary | Change in Glucose level | Measured in g/dL. | Once per week, over 4 weeks | |
Secondary | Change in Insulin level | Measured in mIU/L. | Once per week, over 4 weeks | |
Secondary | Change in leptin level | Measured in ng/mL. | Once per week, over 4 weeks | |
Secondary | Change in beta-Hydroxybutyrate level | Measured in mg/dL. | Once per week, over 4 weeks | |
Secondary | Glucose profile | Using continuous glucose monitoring (CGM), to measured glucose level (g/dL) each day at home. | Continuously measured over 4 weeks | |
Secondary | Change in Body weight (kg) | Once per week, over 4 weeks | ||
Secondary | Change in Oxygen saturation | Measured as a percentage. | Once per week, over 4 weeks | |
Secondary | Change in Blood Pressure | Measured in mmHg. | Once per week, over 4 weeks | |
Secondary | Change in percentage of body fat | The investigators will measure percentage body fat using the Bioelectrical impedance analysis (BIA). | Once every 2 weeks, over 4 weeks | |
Secondary | Change in Apnea Hypopnea Index | The apnea hypopnea index (AHI) is derived from combined information from EEG signals, flow sensors, respiratory belts, and carbon dioxide censors and is a measure of severity of sleep apnea. AHI < 5 is considered normal. AHI 5-15 is considered mild sleep apnea. AHI 15-30 is considered moderate sleep apnea. AHI >30 is considered severe sleep apnea. | Once every 2 weeks, over 4 weeks | |
Secondary | Change in LDL Cholesterol | Measured in mg/dL. | Once per week, over 4 weeks | |
Secondary | Change in HDL Cholesterol | Measured in mg/dL. | Once per week, over 4 weeks | |
Secondary | Change in Triglyceride level | Measured in mg/dL. | Once per week, over 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02845076 -
Weaning From Noninvasive Ventilation
|
N/A | |
Recruiting |
NCT05008211 -
Information-Motivation-Behavioral Skills Model-based Intervention to Domiciliary Non-invasive Ventilation of Patients
|
N/A | |
Recruiting |
NCT03238339 -
The Clinical Application and Popularization of Portable Home Noninvasive Ventilator
|
||
Recruiting |
NCT06047405 -
NIV for Hypercapnic Respiratory Failure: AVAPS vs S/T BIPAP
|
N/A | |
Recruiting |
NCT02874339 -
High Flow Nasal Oxygen Versus VNI in Acute Hypercapnic Cardiogenic Pulmonary Edema
|
N/A | |
Not yet recruiting |
NCT05497986 -
Conventional Low Flow Oxygenation Versus High Flow Nasal Cannula in Hypercapnic Respiratory Failure
|
N/A | |
Completed |
NCT01987661 -
The Effects of Airtrapping on Sleep and Breathing in Non Invasive Ventilation (NIV) in COPD
|
N/A | |
Completed |
NCT03398239 -
Comparison of BPAP ST/T and BPAP ST / T Mode With AVAPS for Hypercapnic Respiratory Failure in ED
|
N/A | |
Terminated |
NCT03353064 -
Telemedicine for Improving Outcome in Inner City Patient Population With Hypercapneic Respiratory Failure
|
N/A | |
Completed |
NCT04072848 -
Mathematically Arterialised Testing of Hypercapnic Subjects Study
|
||
Not yet recruiting |
NCT04131660 -
Efficacy of Volume Ventilation in Patients With Acute Respiratory Failure at Risk of Obstructive Apneas or Obesity Hypoventilation
|
N/A | |
Completed |
NCT02699112 -
Cardiac and Respiratory Function With Non-invasive Ventilation
|
||
Completed |
NCT01523470 -
Withdrawal of Non-invasive Ventilation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Acute Hypercapnic Respiratory Failure
|
Phase 3 | |
Active, not recruiting |
NCT04709562 -
Clinical Stabilization of Hypercapnia: NIPPV v HVNI
|
N/A | |
Not yet recruiting |
NCT06064409 -
Optimal Timing and Failure Prediction of High Flow Nasal Cannula Oxygen Therapy in Emergency Department: Prospective Observational Single Center Study
|
||
Recruiting |
NCT04351906 -
Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome
|
N/A | |
Not yet recruiting |
NCT06367686 -
Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor
|
||
Completed |
NCT03406572 -
Use of Nasal High Flow Oxygen During Breaks of Non-invasive Ventilation for Patients With Hypercapnic Respiratory Failure
|
N/A | |
Active, not recruiting |
NCT03364946 -
High Flow Therapy in ICUs Across Ibero America
|
||
Not yet recruiting |
NCT06257667 -
Treatment of Acute Hypercapnic Respiratory Failure With OptiflowTM or Optiflow+DuetTM Nasal Cannula in COPD-patients
|
N/A |